These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 29232033

  • 1. Amyopathic dermatomyositis with anti-TIF1 gamma antibodies.
    Schiffmann ML, Warneke VS, Ehrchen J.
    J Dtsch Dermatol Ges; 2018 Jan; 16(1):76-78. PubMed ID: 29232033
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y, Ishikawa A, Sugiura K, Akiyama M.
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [Abstract] [Full Text] [Related]

  • 7. Necrotic ulcerations in dermatomyositis: a marker of bad prognosis?
    Borghi A, Corazza M, Mantovani L, Ricci M, Maranini C, Virgili A.
    G Ital Dermatol Venereol; 2016 Jun; 151(3):318-9. PubMed ID: 27176089
    [No Abstract] [Full Text] [Related]

  • 8. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
    Matsuura E, Ishiguro N, Katsumata Y, Urano W, Yamanaka H, Kondo M, Kuwana M, Kaji K, Hamaguchi Y, Fujimoto M, Kawashima M.
    Eur J Dermatol; 2012 Jun; 22(5):668-71. PubMed ID: 22992252
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
    Venalis P, Selickaja S, Lundberg K, Rugiene R, Lundberg IE.
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. TIF1γ-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody.
    Kasuya A, Hamaguchi Y, Fujimoto M, Tokura Y.
    Acta Derm Venereol; 2013 Nov; 93(6):715-6. PubMed ID: 23407650
    [No Abstract] [Full Text] [Related]

  • 15. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
    Shimizu K, Kobayashi T, Kano M, Hamaguchi Y, Takehara K, Matsushita T.
    J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinically amyopathic dermatomyositis in a patient with an extramedullary plasmacytoma of the tongue.
    Orme CM, Zhou LH, Lazic T.
    J Dermatol; 2012 Jul; 39(7):656-7. PubMed ID: 22211639
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Amyopathic dermatomyositis.
    Olsen NJ, Park JH, King LE.
    Curr Rheumatol Rep; 2001 Aug; 3(4):346-51. PubMed ID: 11470054
    [Abstract] [Full Text] [Related]

  • 20. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
    Merlo G, Clapasson A, Cozzani E, Sanna L, Pesce G, Bagnasco M, Burlando M, Parodi A.
    Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.